Taysha Gene Therapies (TSHA) Shares Outstanding (2019 - 2026)

Taysha Gene Therapies has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $366.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 36.14% year-over-year to $366.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $366.6 million (up 36.14% YoY) and the FY2025 annual result came in at $285.1 million, up 39.09% from the prior year.
• Shares Outstanding (Entity) improved to $366.6 million in Q1 2026 per TSHA's latest filing, from $285.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $366.6 million in Q1 2026 and troughed at $38.5 million in Q1 2022.
• A 5-year average of $173.1 million and a median of $187.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) climbed 1.89% in 2022, then soared 212.55% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $44.0 million in 2022, then soared by 164.2% to $116.1 million in 2023, then soared by 76.49% to $204.9 million in 2024, then surged by 39.09% to $285.1 million in 2025, then increased by 28.62% to $366.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $366.6 million, $285.1 million, and $353.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.